The Food and Drug Administration (FDA) gave final approval to magnetic resonance guided focused ultrasound surgery (MRgFUS) on October 27, 2004. Approval of MRgFUS in the United States (U.S.) limits its use to the treatment of uterine fibroids. Evaluation of this technique for use in the abdomen, breasts, and palliative treatment of bone cancer has been ongoing in other parts of the world for quite some time. Together with an internationally known expert in the field, we will explore these and other applications in this exciting new technology.